Micropatterned Mesoderm Assay for Human Developmental Toxicity Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current animal-based and cell-based developmental toxicity testing methods are limited by cost, ethical concerns, and inaccuracies in predicting human developmental toxicity, particularly due to inter-species variations and the inability to reliably classify developmental toxins using human embryonic stem cells.
Innovation Solution
An in vitro method involving micropatterning of extracellular matrix to grow human embryonic stem cells in a mesoendodermal induction medium, forming geometrical mesoendoderm structures, and assessing changes in these structures in the presence of test compounds to identify developmental toxic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If human embryonic stem cells are used to replace mouse ESCs in the EST assay, then the relevance to human developmental toxicity is improved, but the differentiation rate into cardiomyocytes is slower and takes longer time
Solution Approach 1:
The patent changes the differentiation parameter from cardiomyocyte formation to mesoendoderm formation, which occurs faster in human ESCs. By using mesoendodermal induction medium and micropatterning, the assay achieves reliable human toxicity assessment within a shorter time frame (7-10 days) compared to traditional cardiomyocyte-based methods.
Solution Approach 2:
The patent creates a simplified copy of the developmental toxicity assay using human ESCs that differentiates into mesoendoderm cells with geometric patterns. This copying approach maintains the essential toxicity testing function while using human cells that differentiate faster than mouse cells into the relevant cell type.
2Measurement precision
If traditional beating cardiomyocyte monitoring is used, then the measurement of developmental toxicity is possible, but the process lasts for 10 days
Solution Approach 1:
The patent changes the measurement parameter from cardiomyocyte beating (which takes 10 days) to mesoendoderm geometric pattern formation (which completes in 7-10 days). This parameter change enables earlier detection of toxicity effects while maintaining measurement precision through quantitative analysis of differentiation patterns.
Solution Approach 2:
The patent performs preliminary micropatterning of the extracellular matrix before cell differentiation, which guides the cells to form geometric mesoendoderm structures faster. This preliminary structural preparation accelerates the differentiation process and reduces test duration without compromising toxicity assessment accuracy.
3Device complexity
If human ESCs are used without micropatterning, then the assay simplicity is maintained, but the sensitivity and reliability of toxicity classification is reduced
Solution Approach 1:
The patent applies micropatterning to create local geometric structures in the extracellular matrix, which induces localized mesoendoderm differentiation. This local quality modification enhances the reliability of toxicity classification by creating distinct geometric patterns that are sensitive to toxicant effects, while the overall assay remains relatively simple.
4Reliability
If animal-based testing methods are used, then the regulatory acceptance is established, but the cost and ethical issues arise
Solution Approach 1:
The patent creates a human cell-based in vitro model that copies the essential functionality of animal-based toxicity testing. By using human ESCs that differentiate into mesoendoderm cells with geometric patterns, the system provides a morally acceptable and cost-effective alternative that maintains regulatory relevance through human-relevant biology.
Solution Approach 2:
The patent changes the test system from animal-based to human cell-based, fundamentally altering the ethical and cost parameters while maintaining regulatory acceptance. The use of human ESCs with controlled differentiation into mesoendoderm cells provides human-relevant data without the ethical concerns of animal testing.
Data Source
AI summary
A method and system of in vitro developmental toxicity testing comprising the steps of micropatterning an extracellular matrix; growing embryonic stem cells on the micropatterned extracellular matrix in the presence of mesoendodermal induction and testing for change of the geometrical mesoendoderm structure in the presence or absence of a test compound wherein (1) a decrease in mesoendodermal differentiation and/or (2) a change in morphology of the geometrical mesoendoderm structure in the presence of the test compound compared to cells in the absence of the test compound indicates that the test compound is a developmental toxic agent.